REDWOOD CITY, Calif., Dec. 30 /PRNewswire-FirstCall/ -- Maxygen, Inc. , a biopharmaceutical company focused on the development of improved versions of protein drugs, today announced the final results of its modified “Dutch Auction” tender offer, which expired at 5:00 p.m., New York City time, on December 23, 2009.
The total number of shares to be purchased in the tender offer include the 6,557,377 shares Maxygen initially offered to purchase, as well the 787,726 additional shares Maxygen has elected to acquire pursuant to the terms of the tender offer.
Stockholders and investors who have questions or need information about the tender offer may contact the Information Agent for the offering, Okapi Partners LLC at (212) 297-0720 or toll-free (877) 285-5990.
CONTACT: Patrick McHugh, or Bruce H. Goldfarb, both of Okapi Partners LLC,
+1-212-297-0720, info@okapipartners.com
Web site: http://www.maxygen.com/
